This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genor Biopharma Holdings Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

35.8%

Tasso di crescita degli utili

36.3%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	40.0%
Tasso di crescita dei ricavi	111.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

SZSC:6998 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	248	-319	N/A	N/A	1
12/31/2023	95	-480	N/A	N/A	1
12/31/2022	10	-651	N/A	N/A	1
6/30/2022	3	-870	N/A	N/A	N/A
3/31/2022	1	-868	N/A	N/A	N/A
12/31/2021	N/A	-865	-695	-624	N/A
9/30/2021	3	-1,880	-749	-646	N/A
6/30/2021	7	-2,895	-803	-668	N/A
3/31/2021	10	-3,086	-959	-845	N/A
12/31/2020	10	-3,027	-885	-787	N/A
3/31/2020	12	-590	-160	-131	N/A
12/31/2019	13	-522	-138	-111	N/A
12/31/2018	7	-288	-283	-253	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: 6998 is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: 6998 is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: 6998 is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: 6998's revenue (111.7% per year) is forecast to grow faster than the Hong Kong market (9.6% per year).

Ricavi ad alta crescita: 6998's revenue (111.7% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if 6998's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Genor Biopharma Holdings Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita